The bill requires pharmaceutical companies to report to the state when pricing for certain prescription drugs exceeds increases outlined in the bill. The bill also requires the Minnesota Department of Health to post the information on a public website.
Drugs with either depression or suicidal thoughts as potential side effects are some of the most commonly prescribed medications in the United States.
“These medications should not be prescribed to older adults no matter what,” said Taeho Greg Rhee, the study’s lead author.
The study’s authors found dozens of cases in which herbal supplements appeared to have altered a conventional medication’s effectiveness or created harmful side effects.
The findings suggest that simply increasing warnings may not be enough to get people to change their behavior. Even when drivers are told — and remember — the risks, they may not believe them.
Even small gifts (less than $500 a year) had an impact on prescribing, but the larger the monetary worth of gifts, the greater the effect.
In 2015, drugs were found in 43 percent of fatally injured drivers with known test results, while alcohol was found in 37 percent of the drivers.
When purchased outside the country, many prescription medicines cost half or less than they do in the United States.
Even receiving a single free meal increased the physicians’ prescription rates of the four drugs in the study.
According to a U of M study, most physicians are not asking their patients about their use of dietary supplements and other alternative therapies. And many patients don’t disclose that information to their doctors.
Fifty-nine percent of American adults were on at least one prescription drug in 2011 and 2012, up from 51 percent in 1999 and 2000.
A re-analysis of a study that led physicians to prescribe the antidepressant Paxil to millions of adolescents uncovered disturbing evidence that the study’s authors misrepresented the clinical trial’s data.
NOACS — which include Xarelto (rivaroxaban), Eliquis (apixaban), Pradaxa (dabigatran) and Savaysa (edoxaban) — have been on the market in the U.S. since 2010.